Ignite Creation Date:
2024-05-06 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT05995236
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-08-09
Brief Title:
Prostate-Specific Membrane Antigen PSMA Radionuclide Therapy
Sponsor:
Methodist Health System
Organization:
Methodist Health System
Study Overview
Official Title:
Prostate-Specific Membrane Antigen PSMA Radionuclide Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physicians discretion Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physicians discretion
Detailed Description:
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physicians discretion Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physicians discretion
Participants will be followed for two years following the first PSMA procedure During these visits participants will also be asked to report any change in their medications Participants will not need to visit the study doctor more often than their usual treatment unless they have other medical needs However if participants experience any significant change in their medical condition they may be asked to have additional tests such as computed tomography CT scans blood tests etc
Participants will be followed for two years following the first PSMA procedure During these visits participants will also be asked to report any change in their medications Participants will not need to visit the study doctor more often than their usual treatment unless they have other medical needs However if participants experience any significant change in their medical condition they may be asked to have additional tests such as computed tomography CT scans blood tests etc
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None